cemagraphics/E+ via Getty Images Dear Fellow Partners: The Summers Value Fund LP ("the Fund") returned 20.4% net 1 in Q3 2025, beating the Russell 2000 Index ETF (IWM), which returned 12.4%, and the Russell 2000 Value Index ETF (IWN), which returned 12.5%. Year-to-date, the Fund is up 4.9% net 1 , underperforming the IWM (10.3%), and the IWN (8.9%). Since inception, the Fund has delivered a 12.2% annualized net 1 return compared to 6.8% for IWM and 6.1% for IWN. Trailing Period Returns SummersValue Fu ...

Core Insights - Galderma, a leader in the dermatology category, will present updates from its portfolio at the 34th European Academy of Dermatology and Venereology (EADV) congress in Paris from September 17-20, 2025 [1] - The company is committed to addressing various skin conditions and will showcase 12 abstracts, including data on sensitive skin, prurigo nodularis, and atopic dermatitis [1] Company Focus - Galderma emphasizes its dedication to dermatology by participating in significant industry events like the EADV congress [1] - The presentation of 12 abstracts indicates a robust research and development pipeline aimed at enhancing treatment options for skin conditions [1]

Strategic Acquisition - LEO Pharma agreed to acquire global rights for skin disease drug Spevigo from Boehringer [1] - The acquisition strengthens LEO Pharma's portfolio [1] IPO Plans - LEO Pharma is planning an IPO in 2026 [1] Industry Focus - LEO Pharma is a Danish dermatology specialist [1]

Does Red Light Therapy Work? We Had Dermatologists Weigh Inhttps://t.co/l1iluk4Mu8 https://t.co/K84uM7CKjR ...